Development of disease-specific pre-clinical PCS models
Our R&D team is researching methodologies to establish the following disease models for our future clients exclusively employing human donor tissues:
- Non-alcoholic fatty liver disease
- Alcoholic liver disease
- Paracetamol-induced liver toxicity
- Idiopathic pulmonary fibrosis
- Cardiac Fibrosis
- Knee joint tissue slices for modelling arthritis
- Skin tissue models for drug and cosmetics development
- Dupuytrens contracture
Development of new PCS organ platforms
Our R&D team is researching the design of PCS platforms for our future clients to determine the efficacy of their anti-inflammatory and anti-fibrotic molecules in the following human tissues:
- Heart (diseased and normal)
- Normal lung modelled to undergo fibrotic remodelling
- Knee (arthritic)
- Normal skin modelled to undergo fibrotic remodelling
- Dupuytrens disease, excised diseased tissue
Development of enhanced performance PCS
To ensure that our clients are provided with state-of-art technologies, our R&D team are continually researching and upgrading protocols for:
- Tailoring PCS preparation for a range of tissue types
- Enhanced PCS culture conditions for specific tissue types
- Advancements to our PCS bioreactor hardware
- Scaling of PCS to 96-well format enabling medium-throughput drug screening